Using the VAP lipid panel for the detection, evaluation, and treatment of patients “at risk” for CAD

In the past several decades, multiple clinical trials have demonstrated the effects of dyslipidemia beyond low density lipoprotein cholesterol (LDL-C) on predicting risk for atherosclerosis and cardiovascular disease. In recent years there has been a proliferation of lipoprotein markers that, when used with LDL-C, help healthcare providers assess risk of patients on the basis of the cardiovascular risk spectrum. In this review, we will discuss some of the important reasons why traditional lipoprotein testing has failed in high risk populations and how unique lipoprotein testing by the Vertical Auto Profile (VAP) Lipid panel is to provide significant clarity to a difficult disease for its management and treatment. We will also discuss some of the new trials that address newer markers of risk that have robust outcomes even after adjusting for traditional cardiovascular disease risk factors.